PMID- 19236716
OWN - NLM
STAT- MEDLINE
DCOM- 20100615
LR  - 20240316
IS  - 1756-8722 (Electronic)
IS  - 1756-8722 (Linking)
VI  - 2
DP  - 2009 Feb 23
TI  - New dosing schedules of dasatinib for CML and adverse event management.
PG  - 10
LID - 10.1186/1756-8722-2-10 [doi]
AB  - Resistance to imatinib in patients with chronic myelogenous leukemia (CML) or 
      Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has 
      emerged as a significant clinical issue. Dasatinib is a tyrosine kinase inhibitor 
      that has 325-fold greater in vitro activity against native BCR-ABL (breakpoint 
      cluster region-Abelson leukemia virus) compared with imatinib and can overcome 
      primary (intrinsic) and secondary (acquired) imatinib resistance. Here, we review 
      the clinical profile of dasatinib in imatinib-resistant and -intolerant patients 
      and share clinical approaches for managing adverse events (AEs) to ensure maximum 
      patient benefit. References were obtained through literature searches on PubMed 
      as well as from the Proceedings of Annual Meetings of the American Society of 
      Clinical Oncology, the American Society of Hematology, and European Hematology 
      Association. Phase II and III studies of dasatinib in patients with 
      imatinib-resistant or -intolerant CML in any phase or Ph+ ALL were selected for 
      discussion. Dasatinib is currently indicated for the treatment of patients with 
      imatinib-resistant or -intolerant CML or Ph+ ALL. AEs associated with dasatinib 
      are typically mild to moderate, and are usually resolved with temporary treatment 
      interruption and/or dose adjustments. A Phase III dose optimization study showed 
      that in patients with chronic phase (CP) CML, 100 mg once-daily dasatinib 
      improves the safety profile, particularly pleural effusion and thrombocytopenia, 
      while maintaining efficacy compared with the previously recommended dose of 70 mg 
      twice-daily. Dasatinib has a manageable safety profile. For patients with CP CML, 
      a new recommended starting dose of 100 mg once daily has recently been approved. 
      The recommended dose for patients with advanced CML or Ph+ ALL remains 70 mg 
      twice daily.
FAU - Wong, Siu-Fun
AU  - Wong SF
AD  - Western University of Health Sciences, College of Pharmacy, Pomona, CA, USA. 
      siuwong@westernu.edu
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20090223
PL  - England
TA  - J Hematol Oncol
JT  - Journal of hematology & oncology
JID - 101468937
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyrimidines)
RN  - 0 (Thiazoles)
RN  - RBZ1571X5H (Dasatinib)
SB  - IM
MH  - Antineoplastic Agents/administration & dosage/adverse effects
MH  - Dasatinib
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Interactions
MH  - Drug-Related Side Effects and Adverse Reactions/*therapy
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
MH  - Models, Biological
MH  - Pyrimidines/*administration & dosage/*adverse effects
MH  - Thiazoles/*administration & dosage/*adverse effects
MH  - Treatment Outcome
PMC - PMC2649947
EDAT- 2009/02/25 09:00
MHDA- 2010/06/16 06:00
PMCR- 2009/02/23
CRDT- 2009/02/25 09:00
PHST- 2008/12/09 00:00 [received]
PHST- 2009/02/23 00:00 [accepted]
PHST- 2009/02/25 09:00 [entrez]
PHST- 2009/02/25 09:00 [pubmed]
PHST- 2010/06/16 06:00 [medline]
PHST- 2009/02/23 00:00 [pmc-release]
AID - 1756-8722-2-10 [pii]
AID - 10.1186/1756-8722-2-10 [doi]
PST - epublish
SO  - J Hematol Oncol. 2009 Feb 23;2:10. doi: 10.1186/1756-8722-2-10.